SIRS-Lab GmbH and Biosite(R) Incorporated Announce Collaboration to Develop Diagnostics for Sepsis
25 August 2005 - 8:42PM
Business Wire
SIRS-Lab GmbH entered into a collaboration agreement with the
U.S.-based bio-medical company, Biosite(R) Incorporated
(NASDAQ:BSTE) for the evaluation and potential commercialization of
sepsis markers. Under the collaboration, SIRS-Lab will provide
access to selected biomarkers for sepsis. Biosite will then make
antibodies to those selected targets using the Company's
proprietary antibody development process, which combines
immunization of mice and phage display to generate highly diverse
libraries of Omniclonal(R) antibodies with high affinity and low
cross-reactivity. The antibodies will be used to generate assays
for the measurement of the selected biomarker targets in blood
samples. Validated biomarkers will then be assessed for
commercialization potential, with high-value markers added to
Biosite's product development process. "We are delighted to work
with Biosite to evaluate the potential value of our sepsis
biomarkers for clinical diagnostic applications," said Dr. Stefan
Russwurm, SIRS-Lab's chief executive officer. "This agreement
combines the strengths of both companies: Biosite's proven antibody
development and commercialization process for diagnostic products
with our expertise in molecular medicine concerning inflammatory
diseases." "Our Biosite Discovery program is focused on diseases
for which rapid and accurate diagnostic tests are needed. Our
antibody technology allows us to quickly and economically evaluate
potential biomarkers for new tests," said Gunars Valkirs, Ph.D.,
senior vice president Biosite Discovery. "We value SIRS-Lab's
competence in the identification of biomarkers and we are pleased
to have access to their intellectual property in the area of
sepsis." The financial terms of the agreement were not disclosed.
About SIRS-Lab SIRS-Lab, a research driven diagnostics company
located in the BioInstrumentation Center in Jena/Germany, is
focused on the identification, development and commercialization of
novel, proprietary biomarkers. Those biomarkers provide a basis for
the development of diagnostic systems for the early identification
of inflammatory/ immunological host responses as well as for the
early identification of the bacterial causes of infection.
SIRS-Labs mission is the development of new diagnostic systems for
clinical routine diagnostic and therapy monitoring of sepsis and
acute inflammatory diseases. Information on SIRS-Lab can be found
at http://www.sirs-lab.com/. About Biosite Incorporated Biosite
Incorporated is a leading bio-medical company commercializing
proteomics discoveries for the advancement of medical diagnosis.
The Company's products contribute to improvements in medical care
by aiding physicians in the diagnosis of critical diseases and
health conditions. Biosite's Triage(R) rapid diagnostics are used
in approximately 50 percent of U.S. hospitals and in more than 50
international markets. Information on Biosite can be found at
www.biosite.com. Except for the historical information presented
herein, matters discussed in this press release are forward-looking
statements that involve risks and uncertainties that could cause
actual results to differ materially from any future results,
performance or achievements expressed or implied by such
statements. Statements that are not historical facts, including but
not limited to statements that are preceded by, followed by, or
that include the words "will"; "believes"; "should"; "intends";
"anticipates"; "plans"; "expects"; "estimates"; or similar
statements are forward-looking statements. Forward looking
statements include statements about the potential benefits of the
collaboration and license agreement between Biosite and SIRS-Lab,
Biosite's ability to generate antibody libraries of selected
targets and evaluate the diagnostic utility of the targets,
Biosite's ability to develop and commercialize potential products
based on selected targets and Biosite's ability to incorporate any
licensed targets into its product development pipeline. Risks that
should be considered include risks and uncertainties regarding the
discovery and product development process generally, risks
associated with the introduction of competitive products from
companies with greater capital and resources, uncertainties around
the proprietary nature of the targets subject to the collaboration,
expansion or development of a direct sales effort in domestic and
international markets, and risks and expenses associated with
litigation, contract disputes, patent conflicts, product recalls,
manufacturing constraints, backlog, delays or inefficiencies,
shipment problems, seasonal customer demand, the timing of
significant orders, changes in reimbursement policies, regulatory
changes, competitive pressures on average selling prices, and the
other risks detailed in Biosite's most recent Annual Report on Form
10-K, as amended, Quarterly Report on Form 10-Q, and other SEC
filings. Biosite disclaims, any intent or obligation to update
these forward-looking statements. Copies of Biosite's public
disclosure filings are available from its investor relations
department. Biosite(R), Omniclonal(R), Triage(R) and New Dimensions
in Diagnosis(R) are registered trademarks of Biosite Incorporated.
The Company's logo is a trademark of Biosite Incorporated.
Biosite (NASDAQ:BSTE)
Historical Stock Chart
From Jul 2024 to Jul 2024
Biosite (NASDAQ:BSTE)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Biosite (MM) (NASDAQ): 0 recent articles
More SIRS-Lab GmbH News Articles